Studies
All protocols across the Vanq research portfolio. Click a study to drill into its endpoints, cohorts, and adjudication queue.
Active studies
4
Total enrolled
1,076
of 1478 target
Active sites
59
multi-site
Readouts in 12 mo
2
P3 + P1b
Study portfolio
Sorted by primary readout date
RECIST-style longitudinal research workspace
Progression-free survival at 32 weeks · Vanq Oncology Cooperative
Enrolled
314/380
Readout
2026-09
Sites
18
83% enrolled · started 2024-08-12 · 2 arms
ctDNA-guided adjuvant de-escalation
Recurrence-free survival, 24 mo · Vanq Translational Lab
Enrolled
87/160
Readout
2027-Q4
Sites
9
54% enrolled · started 2025-02-04 · 2 arms
Dose-finding TKI + checkpoint combo (HCC)
MTD / DLT-rate at cycle 2 · Vanq Early Phase Unit
Enrolled
22/48
Readout
2026-04
Sites
4
46% enrolled · started 2025-06-22 · 3 arms
Multi-modality surveillance of cirrhotic cohort
Time-to-HCC detection · Vanq Population Health
Enrolled
612/800
Readout
2027-12
Sites
22
77% enrolled · started 2023-11-01 · 1 arm
Neoadjuvant cytotoxic + immunomodulator window-of-opportunity
Pathologic complete response · Vanq Surgical Oncology Group
Enrolled
41/90
Readout
TBD
Sites
6
46% enrolled · started 2024-12-01 · 2 arms